January 2024 in “International Journal of Molecular Sciences” This study found that subcutaneous injection of a CXCL12 neutralizing antibody significantly promoted hair growth in androgenic alopecia and inhibited hair loss in alopecia areata in mouse models, suggesting its potential as a promising treatment for hair loss.
November 2023 in “Cell Proliferation” This study found that adipose-derived stem cells with DKK1 knocked out using CRISPR/Cas9 promoted hair growth in an alopecia areata model more effectively than untreated stem cells, suggesting DKK1 is a potential therapeutic target for this condition.
This review concluded that the efficacy of cosmeceutical hair serums for addressing hair loss lies in their use of bioactive peptides and plant compounds, like flavonoids and sterols, that target eight key contributing factors identified in hair loss conditions.
1 citations
,
May 2023 in “Prospects in Pharmaceutical Sciences” This study reviews current treatments for alopecia areata, highlighting that despite various options like corticosteroids and immunosuppressives, their limited efficacy and potential side effects are challenges, while targeting specific cytokines has shown promise except with TNF inhibitors, which may worsen the condition.
This review highlights that nanotechnology offers promising avenues for enhancing drug delivery and developing new therapeutic strategies for androgenetic alopecia, though challenges remain in clinical translation and the need for long-term safety studies.
May 2023 in “Clinical, Cosmetic and Investigational Dermatology” This review examines the efficacy of various novel treatments for androgenetic alopecia, including oral minoxidil and platelet-rich plasma, suggesting potential benefits but emphasizing the need for further high-quality clinical trials to thoroughly evaluate their effectiveness.
December 2022 in “International Journal of Pharmaceutics” This study estimated the starting dose range for a finasteride long-acting injectable formulation in humans, suggesting that 16.80 mg may be the optimal starting dose.
November 2022 in “Molecular Pharmaceutics” This study found that intradermal injection of a cell-penetrating, AR-targeting asiRNA promoted hair growth and reduced androgen receptor expression in mouse models of androgenetic alopecia, suggesting its therapeutic potential.
1 citations
,
July 2022 in “JEADV Clinical Practice” This abstract outlines a guide reviewing both FDA-approved and off-label therapies for androgenetic alopecia and proposes treatment algorithms based on scientific research, highlighting a gap in common treatments for this prevalent condition.
April 2022 in “Biomedicine & Pharmacotherapy” This study found that CXCL12 inhibits hair growth via the CXCR4/STAT signaling pathway, suggesting that targeting this pathway could be a promising approach for promoting hair growth.
17 citations
,
November 2021 in “Journal of Cosmetic Dermatology” This review discusses treatment options for androgenetic alopecia, highlighting the need for personalized, evidence-based approaches but reports no new clinical results.
August 2021 in “Annales pharmaceutiques françaises” This study used computer simulations to evaluate the absorption of oral and topical finasteride for treating androgenetic alopecia, finding that topical applications resulted in lower plasma concentrations, suggesting potential viability as a treatment option.
1 citations
,
January 2021 in “Skin appendage disorders” This case report describes a 21-year-old woman with progressive alopecia areata who experienced hair regrowth while treated with tocilizumab for posterior uveitis, suggesting the potential for this drug to affect hair loss and regrowth by disrupting interleukin-6 signaling.
102 citations
,
July 2020 in “International journal of molecular sciences” This review discusses the effects of hormonal changes on hair follicles, concluding that hormones like androgens and estradiol significantly influence hair growth and cycle, while the roles of other hormones are still being researched.
15 citations
,
June 2020 in “Experimental Dermatology” This review discusses recent genetic findings on hormonal signaling pathways in androgenetic alopecia, reporting no new study results but highlighting the need for further investigation.
7 citations
,
September 2019 in “Journal of The American Academy of Dermatology” This study found inflammation and fibrosis in both pattern hair loss cases and controls but concluded that these factors may not significantly contribute to the pathogenesis of pattern hair loss.
9 citations
,
January 2019 in “American Journal of Dermatopathology” This study found that both androgenetic alopecia and alopecia areata showed significantly increased DKK-1 expression, potentially implicating it in the pathogenesis and as a treatment target for these conditions.
39 citations
,
March 2018 in “Archives of Dermatological Research” This review describes the molecular interactions between androgens and Wnt/ß-catenin signaling in androgenetic alopecia but reports no new experimental or clinical findings; the authors discuss potential Wnt/ß-catenin-targeted treatments for hair growth.
35 citations
,
September 2017 in “PubMed” This article reviews different types of alopecia, their diagnosis, and treatment options available in a family physician's practice, but it reports no new research findings.
77 citations
,
June 2017 in “Advances in Therapy” This review discusses recent advances and ongoing clinical trials in novel therapeutics for alopecia areata, despite the lack of current FDA-approved treatments for severe cases, and reports no new results.
27 citations
,
April 2017 in “British Journal of Dermatology” This study identified overexpression of certain immune-related genes and underexpression of genes in specific signaling pathways in premature androgenetic alopecia, suggesting potential new therapeutic targets.
May 2016 in “DOAJ (DOAJ: Directory of Open Access Journals)” This study found that vertex accentuation is the second most common pattern of female pattern hair loss in Asian women, following the diffuse type.
14 citations
,
August 2015 in “Endocrinology” This study describes the development of a monoclonal antibody, 005-C04, which blocks PRLR-mediated signaling, suggesting its potential for furthering understanding of PRLR's role in health and disease.
10 citations
,
July 2015 in “Journal of Cosmetic Dermatology” This study found elevated tissue levels of DKK-1 in patients with both androgenetic alopecia and alopecia areata compared to controls, suggesting DKK-1 as a potential therapeutic target for these conditions.
46 citations
,
June 2015 in “Journal of Investigative Dermatology” This study found that androgen receptor activation in adult mouse skin reduces β-catenin-induced hair follicle growth and sebaceous gland conversion, highlighting its role in stem cell fate decisions.
50 citations
,
July 2014 in “International Journal of Clinical Pharmacology and Therapeutics” This study found that both topical and oral finasteride significantly reduced plasma DHT after one week, with lower finasteride plasma exposure for the topical formulation.
6 citations
,
August 2013 in “Joint Bone Spine” Tocilizumab treatment was associated with significant hair regrowth in one patient and temporary hair loss followed by regrowth in another.
95 citations
,
January 2012 in “British Journal of Dermatology” This study found that androgens inhibit hair follicle stem cell differentiation by disrupting the Wnt signalling pathway in dermal papilla cells, but Wnt activation can restore differentiation.
19 citations
,
January 2012 in “Dermato-endocrinology” This study suggests that moderate elevated prolactin levels are unlikely to cause significant hair loss in women, but still warrant further diagnostic investigation to rule out a prolactin-producing pituitary tumor.
173 citations
,
September 2011 in “Journal of Investigative Dermatology” IL-6 contributes to hair loss by shortening the growth phase and causing hair follicles to regress.
1 citations
,
January 2010 in “Springer eBooks” This review discusses the role of androgen metabolism and perifollicular inflammation in the progression of androgenetic alopecia and reports no new clinical results.
36 citations
,
November 2009 in “Journal of Investigative Dermatology” This study suggests that prolactin has complex, gender- and location-dependent effects on human hair follicles, promoting hair growth in female frontotemporal scalp areas while inhibiting it in male occipital regions.
171 citations
,
July 2007 in “Journal of Investigative Dermatology” The researchers reported that DHT-inducible DKK-1 may play a significant role in DHT-driven balding by inhibiting hair follicle cell growth and promoting apoptosis in androgenetic alopecia.
53 citations
,
November 2006 in “Journal of Endocrinology” This study found that prolactin plays a direct role in regulating the timing of hair growth cycles in mice by affecting the skin, rather than through other endocrine factors.
128 citations
,
March 2006 in “American Journal of Pathology” The study found that prolactin expressed in human scalp hair follicles acts as an autocrine modulator, inhibiting hair growth and promoting hair follicle regression, which may contribute to hair loss in hyper-prolactinemia patients.
91 citations
,
May 2003 in “American Journal of Pathology” This study found that prolactin and its receptor are expressed in the murine hair follicle epithelium, influencing hair cycle phases by down-regulating keratinocyte proliferation during anagen and inducing premature catagen.
231 citations
,
December 1999 in “Journal of Investigative Dermatology” This study found that the volume of a hair follicle's dermal papilla is strongly correlated with its size, primarily due to the number of cells it contains and the volume of extracellular matrix.
370 citations
,
September 1999 in “The New England Journal of Medicine” This article discusses the treatment of androgenetic alopecia and alopecia areata with finasteride and minoxidil but reports no new clinical results.
